Brief: Eloxx Pharmaceuticals Provides Update On The Impact Of Novel Coronavirus On Phase 2 Clinical Trials In Cystic Fibrosis
25/03/2020 13:07
March 25 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS PROVIDES UPDATE ON THE IMPACT OF
NOVEL
CORONAVIRUS (COVID-19) ON PHASE 2 CLINICAL TRIALS IN CYSTIC
FIBROSIS
* ELOXX PHARMACEUTICALS INC - ENROLLMENT IN PHASE 2 CYSTIC
FIBROSIS TRIALS HAS BEEN PAUSED TEMPORARILY IN RESPONSE TO
COVID-19 PANDEMIC
* ELOXX PHARMA - COMMITTED TO COMPLETING ENROLLMENT IN PHASE
2
PROOF OF CONCEPT CLINICAL TRIAL PROGRAM & REPORTING TOP LINE
DATA AS SOON AS FEASIBLE
Source text for Eikon: ID:nGNX4DDX37
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome